GARY A. ASCANI
Chief Executive Officer and President
Gary A. Ascani has over 30 years of experience in marketing, sales and general management in the biotechnology/medical products industry. Mr. Ascani has held management and executive positions with Hyland Labs, a Division of Baxter–Travenol, Chicago, IL; Monoclonal Antibodies, Inc. a biotechnology company located in Mt. View, CA; Molecular Analysis, Inc., a biotechnology start-up in Houston, TX; T Cell Diagnostics, a biotechnology start-up in Cambridge, MA; and Diamedix, Inc. a division of Ivax Corp. Miami, FL.

In 1999, Mr. Ascani co-founded Vulcan Medical Ventures, Inc., Birmingham, Alabama (VMV), a small venture capital firm focused on seed stage venture financing. In 2001, VMV closed a Series A Preferred Stock Financing for PNP Therapeutics, Inc. (PNP Inc.) at which time Mr. Ascani became PNP Inc.'s Chairman and CEO. PNP Therapeutics, Inc. is an early-stage biopharmaceutical company that is developing a platform technology and proprietary products for the treatment of cancer.

Mr. Ascani continues to serve as a member of PNP Inc's Board of Directors. Prior to relocating to Gainesville, Florida, Mr. Ascani served as a member of the Board of Directors of the Birmingham Venture Club, a member of the Executive Committee of the Board of Directors and Treasurer of the Biotechnology Association of Alabama and was honored by the Birmingham Business Journal with his selection to the first annual "Who's Who in Health Care."